Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.
Liposomal daunorubicin (DaunoXome) is a formulation of the anticancer drug daunorubicin encapsulated into vesicles of about 45 nm diameter. To understand the pharmacodynamic relationships associated with the toxicity and efficacy of liposome-encapsulated daunorubicin in vivo and in vitro, it is essential to have a rapid method of separating the free and liposomal forms of the drug. We have developed and validated a method to quantify drug concentrations of liposomal daunorubicin, free daunorubicin and its main metabolite daunorubicinol that requires only 50 microl of plasma to conduct studies in children. The method involves the use of solid-phase extraction followed by capillary electrophoresis with laser-induced fluorescence (LIF) detection. With LIF detection a limit of quantification of 1 microg/l is obtained for the free form and the metabolite. Precision and accuracy are in accordance with the generally accepted criteria for bioanalytical methods. The method is rapid and allows for multiple samples to be processed simultaneously.